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Notwithstanding recent advances in research and drug 
discovery, the drug development pipeline for tropical dis- 
eases is drying up.’ Despite the ever-increasing demand 
for effective, safe, and affordable drugs, tropical diseases, 
by their nature and prevalence, are a low priority for pri- 
vate industry. 
The authors analyzed the drug development process 
with particular emphasis on the top ranking six groups 
of parasitic diseases in terms of morbidity and mortality 
(filariasis, helminthic infections, African trypanosomiasis, 
leishmaniasis, malaria, and schistosomiasis). Data were 
retrieved through systematic search of the medical press 
(through MEDLINE Database, 1994 to 1997; Drugs and 
Pharmacology Embase, 1986 to 1997), pharmaceutical 
statistics (IMS International data) and the World Health 
Organization (WHO) reports. 
Of the 1223 new chemical entities commercialized 
worldwide between 1975 and 1996,379 were real ther- 
apeutic innovations.2 Less than 1% (11 new molecules, 
plus two new approvals for reformulation of known 
chemical entities) were destined for tropical diseases, of 
which only a minority may be claimed by Western phar- 
maceutical companies as genuine products of their 
research, the majority being either “incidental” discover- 
ies recovered from veterinary medicine or molecules dis- 
covered by governmental or academic institutions and 
only later acquired and commercialized by the Western 
industry. Furthermore, atovaquone development for 
malaria would have been endangered if its effectiveness 
in acquired immunodeficiency syndrome (AIDS)-related 
opportunistic infections had not been discovered. In addi- 
tion, various artemisinin-type drugs in use do not meet 
international standards and are registered only in the 
country of origin and few other countries (Table 1). 
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What prevents drug companies from conducting 
research and development (R&D) for tropical diseases, 
against the current scenario of high awareness of emerg- 
ing infections and particularly malaria? 
First, the cost:risk ratio of drug R&D is compounded 
by the low purchasing power of the endemic countries. 
The average cost of bringing a new chemical entity to the 
market, a process taking 8 to 12 years,? is US$l60 million 
(although some claim more), with “only” US$l6 to 54 mil- 
lion of this allocated to clinical development,* hence the 
advantage of “piggy-backing” on other discovery efforts. 
As Western drug companies expand through repeat merg- 
ers, the target in terms of sales for a development can- 
didate grows higher, and tropical diseases drop down the 
priority list. Donation programs (e.g., ivermectin, ato- 
vaquone) are often preferred to dual-pricing for wealthy 
and indigent customers, as the latter strategy could jeop- 
ardize sales of high-priced compounds also marketed for 
nonparasitic indications. 
Second, the protection of proprietary rights and the 
recovery of investments also are important issues to drug 
makers. With the long payback period associated with 
these indications, costs often are not recovered when a 
compound runs off patent and generic products may be 
introduced. A sales decline of over 50% is expected within 
the fast few months of generic entry.3 Moreover, unfair 
competition and counterfeit products are not uncommon. 
Lastly, regulatory requirements have a considerable 
impact on the length and costs of the process and, hence, 
on the ultimate market price of the product. Paradoxi- 
cally, increasingly demanding standards favor the larger 
wealthy companies, which are those least interested in 
tropical diseases. Nevertheless, dossiers do not necessar- 
ily undergo the same level of review the world over, some- 
times because of bare-bones health budgets, and 
sometimes owing to a misconception of the regulatory 
process. 
The net result is that fewer drugs adapted to the 
needs of the poor are anticipated. The immediate pipeline 
sounds rich: there are new antimalarial and antileishma- 
nial drugs (see Table 1) in clinical phases of development 
or nearing registration, but few developments are need- 
driven. Some compounds are predictably expensive, and 
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Table 1. Characteristics of Drug Development Output 
Indication 
Molecular 
Entities 
Year First 
Marketed or 
Approved Pharmaceutical Development Context 
Pricing and 
Marketing Strategy 
Marketing approval of new molecular entities: 1975-1997 
Malaria 
Human African 
trypanosomiasis 
(HAT) 
Chagas’ disease 
Schistosomiasis 
Helminthic 
infections 
Onchocerciasis 
Artemether * 
(intramuscular) 
Atovaquone / 
proguanil 
Halofantrine 
Mefloquine 
Eflornithine 
(DFMO) 
Benznidazole 1981 
Nifurtimox 1984 
Oxamniquine 1981 
Praziquantel 1980 
Albendazole 
lvermectin 
1997 
1997 
1989 
1987 
1990 
1987 
1989 
Chinese academy discovery. Public-private 
collaboration (WHO-TDR / Rhone-Poulenc-Rorer 
Co.). RPR / Kunmig Co. (China) agreement 
Wellcome antimalarial research (now GlaxoWellcome 
Co.). Atovaquone first approved for Pneumocystis 
carinii infection in HIV/ AIDS 
US DOD discovery &J/RAIR). Public-private 
collaboration (WHO / WRAIR / SmithKline 
Beecham Co.). US Orphan Drug status 
US DOD discovery (WRAIR). Public-private 
collaboration (WHO / WRAIR / Hoffman LaRoche) 
US Orphan Drug status 
Marion Merrell Dow (now Hoechst Marion Roussel Co.). 
US orphan product designation and approval for the 
treatment of HAT (% b. gambiense) 
Veterinary originally (Roche Co.) 
Veterinary R&D originally (Bayer Co.) 
Veterinary R&D originally (Pfizer Co.) 
Veterinary R&D originally (Bayer Co.). Public-private 
collaboration (WHO / Bayer) 
Veterinary R&D originally (SmithKline Beecham Co.) 
Veterinary R&D originally (Merck Co.). Public-private 
collaboration (WHO / Merck) 
Preferential price for public 
sector. Artemether from other 
manufacturers cheaper 
Very expensive (high cost of 
goods). Currently partial drug 
donation programme 
Expensive: producer price 
Expensive, but cheaper generic 
products exist 
Very expensive. Product originally 
abandoned by HMR. WHO 
efforts to restart and to reduce 
price considered 
Producer price 
Producer price 
Producer price 
Producer price and generic 
products 
Drug donation under 
consideration 
Mectizan-donation programme 
New approvals for already-marketed drug products in a new use or a reformulation 
Human African Pentamidine 1950/ 
typanosomiasis isethionate 1984 
Leishmaniasis Amphotericin B 1962 / 
lipid complex 1996 
Possible future additions 
Malaria Artemether / 1998? 
benflumetol 
Pyronaridine 2000 ? 
Leishmaniasis 
Artesunate 1999? 
rectal 
Etaquine ? 
Chlorproguanil / 2000? 
dapsone 
Arteether 1998? 
Artelinate ? 
Paromomycin 1999? 
(aminosidine) 
WR6026 ? 
Miltefosine ? 
Rhone-Poulenc Co.: galenic reformulation (mesylate 
to isethionate). US Orphan Drug status and new 
approval only for FI carinii infection 
Vestar (now NeXstar Co.): galenic reformulation of 
amphotericin B in liposomes. US Orphan Drug 
status and approval for treatment of invasive 
fungal infections 
Drug donation for HAT (through 
WHO) 
Extremely expensive 
Efforts to cut price inconclusive 
as yet 
Ciba Geigy (now Novartis Co.) Probably expensive 
Strategy unknown 
Chinese academy discovery marketed only in China, Unknown 
International development by WHO-TDR, currently 
no industrial partner 
Chinese academy discovery; international development 
for limited indication by WHO-TDR and Mepha Co. 
US DOD discovery (WRAIR). Public-private 
collaboration (WRAIR / SmithKline Beecham Co.) 
Combination of known antimalarials. Public-private 
collaboration (WHO-TDR / SmithKline Beecham Co.) 
Public-private collaboration (Gov. of the Netherlands/ 
Artecef / WHO-TDR / WRAIR) 
US DOD (WRAIR) 
Re-discovery of old aminoglycoside by Farmitalia-Carlo 
Erba (now Pharmacia-Upjohn Co.) developed by 
WHO-TDR, currently no industrial partner. 
US Orphan Drug designation (1994) for the treatment 
of visceral leishmaniasis 
US DOD discovery (WRAIR). Public-private collaboration 
(WRAIR / SmithKline Beecham Co.) 
Product under development as anticancer agent. Public- 
private collaboration (WHO-TDR / Asta Medica Co.) 
*There are other sources and formulations of attemether and other artemisinin-type compounds (artemisinin, artesunate, dihydroartemisinin, arteether in various 
formulations) that have received marketing approval in country of origin (mostly China and Vietnam) and few neighboring countries, or are under development. 
WRAIR = Walter Reed Army Institute of Research; WHO /TDR = World Health Organization/Special Programme for Research and Training in Tropical Diseases. 
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no further candidate for development is expected in the 
short term. 
This and prior analyses call for a broader debate on 
global drug development strategies for tropical diseases. 
The present profit-driven system is obviously unable to 
keep pace with current and evolving needs, and so far the 
public sector (with few exceptions) has been unable to 
provide the optimal environment for such activities. 
There is clearly room for new approaches. Increased 
representation of disease-endemic countries in the 
process is needed. The antimalarial drug market in par- 
ticular offers opportunities poorly covered by Western 
drug companies. What is not appealing to the Western 
drug industry may well be suited to small-to-medium sized 
start-up companies, particularly in advanced developing 
countries. Opportunities exist: basic research in acade- 
mia generates leads that are not exploited and candidate 
agents that are not developed. The Special Programme 
for Research and Training in Tropical Diseases (TDR) stim- 
ulates projects along these lines, providing training oppor- 
tunities for scientists from advanced developing 
countries, facilitating technology transfer to the public 
and private sectors, and strengthening research and infra- 
structure. The public and private sectors should explore 
the facilitation of interaction, alternative routes of mar- 
keting and distribution (purchase funds), and optimizing 
the regulatory process. The momentum around malaria 
with the newly established Roll Back Malaria Initiative of 
the WHO could, hopefully, break new ground. 
ACKNOWLEDGMENTS 
The authors thank F? Etienne Barral, for his contribution to the 
pharmaceutical data study, and Mrs. L. Baldry, for reviewing the 
manuscript. 
REFERENCES 
1. Olliaro P Will the fight against tropical diseases benefit from 
orphan drug status? Trop Med Intern Health 1997; 2:113-115. 
2. Trouiller l? Recherche et developpement pharmaceutiques 
en matiere de maladies transmissibles dans la zone intertro- 
picale. Cah Sante 1996; 6:299-307. 
3. Mehl B, Santell JP Projecting future drug expenditures, 1998. 
Am J Health Syst Pharm 1998; 55:127-136. 
4. Grabowski H. The effect of pharmacoeconomics on com- 
pany research and development decisions. Pharmacoeco- 
nomics 1997; 5:389-397. 
5. Love J. Call for more reliable costs data on clinical trials. 
Marketletter 1997; January 13: 24-25. 
